LINC01749: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01749

NCBI ID: G63930

LINC01749

Other Name(s): long intergenic non-protein coding RNA 1749 | Long intergenic non-protein coding RNA 1749

LINC01749: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC01749 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarkers. This RNA has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and invasion. LINC01749 is also known as linc01749-containing exons, LINC01749-containing exons (LINCE), or HO-1749.9.

Drug Targets

LINC01749 has been identified as a potential drug target due to its involvement in several cellular processes that are associated with the development and progression of various diseases, including cancer. LINC01749 has been shown to play a role in the regulation of the cell cycle, cell adhesion , and the process of cell migration.

One of the key drug targets associated with LINC01749 is the PI3K/Akt signaling pathway. This pathway is known to be involved in the regulation of several cellular processes, including cell growth, differentiation, and survival. LINC01749 has been shown to play a role in the regulation of PI3K/Akt signaling by negatively regulating the activity of the protein kinase Akt.

Another potential drug target associated with LINC01749 is the TGF-β signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is known to be involved in the development and progression of several diseases, including cancer. LINC01749 has been shown to play a role in the regulation of TGF-β signaling by negatively regulating the activity of the protein kinase Smad.

Biomarkers

LINC01749 has also been identified as a potential biomarker for several diseases, including cancer. This RNA has been shown to have potential in diagnosing and monitoring the progression of various diseases, including cancer.

One of the key biomarkers associated with LINC01749 is its expression level. Studies have shown that LINC01749 is downregulated in several diseases, including cancer, and its expression level can be used as a biomarker for disease diagnosis and monitoring.

Another biomarker associated with LINC01749 is its expression level in certain cancer types, such as lung cancer. Studies have shown that LINC01749 is downregulated in lung cancer and its expression level can be used as a biomarker for disease diagnosis and monitoring.

Conclusion

In conclusion, LINC01749 is a long intergenic non-protein-coding RNA that has been identified as having potential drug targets and biomarkers. Its involvement in the regulation of cellular processes, including cell adhesion, migration, and the PI3K/Akt and TGF-β signaling pathways, makes it a promising target for the development of new drugs. Its potential as a biomarker for several diseases, including cancer, makes it an attractive candidate for diagnostic tools. Further research is needed to fully understand the role of LINC01749 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1749

The "LINC01749 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01749 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets